SAM-e and glucosamine continue to be of clinical interest: the first trial of the two in combination will take place in 2002.
| Joint Action in the Treatment of Arthritis |
| Investigators |
John Bradley, Michael Weisman, Betsy Singh |
| Location |
Cedars Sinai Medical Center |
| Type of Study |
Randomized, double blind, placebo controlled |
| # subjects |
88+ |
| Dose |
SAM-e 600 mg/day; glucosamine 1500 mg/day |
| Duration |
8 weeks |
| Overview |
There is a significant population of patients with early-onset arthritis who have a difficult time coping with their disease. The use of Joint Action has the dual benefit of mood elevation and arthritis relief. |
PharmaviteŽ LLC financially supports these clinical research initiatives.
|
